Boston Scientific (BSX) PT Raised to $120 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Boston Scientific (BSX) PT Raised to $122 at Citi
February 5, 2025 2:06 PM ESTCiti analyst Joanna Wuensch raised the price target on Boston Scientific (NYSE: BSX) to $122.00 (from $107.00) while maintaining a Buy rating.
The analyst commment "BSX delivered another strong quarter meaningfully surpassing consensus, with four of the eight segments delivering double-digit growth, including Electrophysiology sales... More
Boston Scientific (BSX) PT Raised to $120 at BTIG
February 5, 2025 2:00 PM ESTBTIG analyst Marie Thibault raised the price target on Boston Scientific (NYSE: BSX) to $120.00 (from $101.00) while maintaining a Buy rating.
The analyst comments "High-flying BSX reported another strong quarter, posting Q4 revenue of $4.561B (+22.4% rep., +19.5% org.) and adj. EPS of $0.70 (consensus: $4.416B and $0.66), well above its guidance of 14-16% organic sales growth and $0.64-$0.66 adj. EPS. The beat was once again led by Electrophysiology which grew ~172% y/y to $649M (consensus $575M), driven by Farapulse, which surpassed $1B in global revenue in 2024. Watchman grew 20% y/y org. to $413M, above consensus of $406M,... More
Boston Scientific (BSX) PT Raised to $115 at BofA Securities
February 5, 2025 12:52 PM ESTBofA Securities analyst Travis Steed raised the price target on Boston Scientific (NYSE: BSX) to $115.00 (from $110.00) while maintaining a Buy rating.
... MoreBoston Scientific reports above-consensus Q4 results, provides outlook
February 5, 2025 7:02 AM ESTInvesting.com -- Boston Scientific (NYSE: BSX) reported fiscal Q4 2024 results that surpassed analyst expectations.
The company's shares swung between gains and losses in premarket trading Wednesday.
The company reported earnings per share (EPS) of $0.70, topping analyst expectations of $0.66.... More
Boston Scientific (BSX) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY25 EPS Guidance
February 5, 2025 6:43 AM ESTBoston Scientific (NYSE: BSX) reported Q4 EPS of $0.70, $0.04 better than the analyst estimate of $0.66. Revenue for the quarter came in at $4.56 billion versus the consensus estimate of $4.41 billion.
GUIDANCE:
Boston Scientific sees FY2025 EPS of $2.80-$2.87, versus the consensus of... More
Boston Scientific (BSX) PT Raised to $115 at Piper Sandler
February 3, 2025 8:19 AM ESTPiper Sandler analyst Matt O'Brien raised the price target on Boston Scientific (NYSE: BSX) to $115.00 (from $95.00) while maintaining a Overweight rating.... More
